Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia

• Status: Completed
• Trial end date: 2014-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate efficacy and safety of HL-040XC in patients with essential hypertension and hyperlipidemia

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: HanAll BioPharma Co., Ltd.
• Treatments: Atorvastatin; Atorvastatin Calcium; Losartan

Criteria

Inclusion Criteria:

• Aged between 18 and 80 years

• History of essential hypertension and hyperlipidemia

• Able to sign informed consent

Exclusion Criteria:

• At screening, SBP ≥ 180mmHg or DBP ≥ 110mmHg or LDL-C > 250mg/dL or TG ≥ 400mg/dL

• Has a history of hypersensitivity to Angiotensin Ⅱ receptor blocker or HMG-CoA reductase inhibitor or component of this drug